Literature DB >> 21977368

Rapid response of disabling tardive dyskinesia to amantadine: a case report.

Gaurav Jain1.   

Abstract

Entities:  

Year:  2011        PMID: 21977368      PMCID: PMC3184560          DOI: 10.4088/PCC.10l01098

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN: 2155-7780


× No keyword cloud information.
  13 in total

1.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

2.  How to examine patients using the Abnormal Involuntary Movement Scale.

Authors:  M R Munetz; S Benjamin
Journal:  Hosp Community Psychiatry       Date:  1988-11

3.  Amantadine hydrochloride treatment of tardive dyskinesia.

Authors:  B L Decker; J M Davis; D S Jonowsky; M K el-Yousef; H J Sekerke
Journal:  N Engl J Med       Date:  1971-10-07       Impact factor: 91.245

Review 4.  Tardive dyskinesia: prevalence, incidence, and risk factors.

Authors:  J M Kane; M Woerner; J Lieberman
Journal:  J Clin Psychopharmacol       Date:  1988-08       Impact factor: 3.153

5.  Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration.

Authors:  R M Allen
Journal:  Biol Psychiatry       Date:  1982-06       Impact factor: 13.382

6.  Amantadine in tardive dyskinesia.

Authors:  M D Merren
Journal:  N Engl J Med       Date:  1972-02-03       Impact factor: 91.245

7.  A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia.

Authors:  S Angus; J Sugars; R Boltezar; S Koskewich; N M Schneider
Journal:  J Clin Psychopharmacol       Date:  1997-04       Impact factor: 3.153

Review 8.  The current status of tardive dyskinesia.

Authors:  P S Sachdev
Journal:  Aust N Z J Psychiatry       Date:  2000-06       Impact factor: 5.744

Review 9.  Tardive dyskinesia.

Authors:  Karla Soares-Weiser; Hubert H Fernandez
Journal:  Semin Neurol       Date:  2007-04       Impact factor: 3.420

Review 10.  Classification and treatment of tardive syndromes.

Authors:  Hubert H Fernandez; Joseph H Friedman
Journal:  Neurologist       Date:  2003-01       Impact factor: 1.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.